Microbubbles versus Extracellular Vesicles as Therapeutic Cargo for Targeting Drug Delivery
Source abstract
Abstract
Extracellular vesicles (EVs) and microbubbles are nanoparticles in drug-delivery systems that are both considered important for clinical translation. Current research has found that both microbubbles and EVs have the potential to be utilized as drug-delivery agents for therapeutic targets in various diseases. In combination with EVs, microbubbles are capable of delivering chemotherapeutic drugs to tumor sites and neighboring sites of damaged tissues. However, there are no standards to evaluate or to compare the benefits of EVs (natural carrier) versus microbubbles (synthetic carrier) as drug carriers. Both drug carriers are being investigated for release patterns and for pharmacokinetics; however, few researchers have focused on their targeted delivery or efficacy. In this Perspective, we compare EVs and microbubbles for a better understanding of their utility in terms of delivering drugs to their site of action and future clinical translation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · Ultrasound and Hyperthermia Applications · Photoacoustic and Ultrasonic Imaging
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute for Immunity and Transplantation, Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University, Palo Alto, California 94304, United States
Department of Molecular Medicine, School of Medicine, Stanford University, Stanford, California 94305, United States
References (77)
Show source-provided references
1. 10.1016/j.jare.2018.06.00510.1016/j.jare.2018.06.005 ↗
2. 10.1186/s13287-019-1468-610.1186/s13287-019-1468-6 ↗
3. 10.3390/ijms1808161010.3390/ijms18081610 ↗
4. 10.1007/s12094-019-02131-w10.1007/s12094-019-02131-w ↗
5. 10.2174/15680261079138418010.2174/156802610791384180 ↗
6. 10.1016/j.ultras.2007.11.00210.1016/j.ultras.2007.11.002 ↗
7. 10.1016/j.jconrel.2019.08.02310.1016/j.jconrel.2019.08.023 ↗
8. 10.1016/j.addr.2020.07.00510.1016/j.addr.2020.07.005 ↗
9. 10.1007/s13534-017-0016-510.1007/s13534-017-0016-5 ↗
10. 10.1016/j.cell.2016.01.04310.1016/j.cell.2016.01.043 ↗
11. 10.1124/pr.112.00598310.1124/pr.112.005983 ↗
12. 10.1109/TBME.2014.238565110.1109/TBME.2014.2385651 ↗
13. 10.1016/j.ultrasmedbio.2018.07.02610.1016/j.ultrasmedbio.2018.07.026 ↗
14. 10.1021/acs.langmuir.8b0388210.1021/acs.langmuir.8b03882 ↗
15. 10.1021/acs.chemrev.7b0053410.1021/acs.chemrev.7b00534 ↗
16. 10.1021/acsnano.6b0760710.1021/acsnano.6b07607 ↗
17. 10.1021/acssensors.9b0216510.1021/acssensors.9b02165 ↗
18. 10.18632/oncotarget.2702110.18632/oncotarget.27021 ↗
19. 10.1161/CIRCRESAHA.117.31075210.1161/CIRCRESAHA.117.310752 ↗
20. 10.1080/20013078.2020.178386910.1080/20013078.2020.1783869 ↗
21. 10.15252/emmm.20160627110.15252/emmm.201606271 ↗
22. 10.1021/acs.accounts.9b0010910.1021/acs.accounts.9b00109 ↗
23. 10.1021/acsnano.8b0205310.1021/acsnano.8b02053 ↗
24. 10.1021/acsanm.0c0165410.1021/acsanm.0c01654 ↗
25. 10.3402/jev.v4.3008710.3402/jev.v4.30087 ↗
26. 10.1146/annurev-pharmtox-010814-12463010.1146/annurev-pharmtox-010814-124630 ↗
27. 10.1038/nrd141710.1038/nrd1417 ↗
28. 10.1021/acsami.9b1018810.1021/acsami.9b10188 ↗
29. 10.1161/CIRCRESAHA.120.31734810.1161/CIRCRESAHA.120.317348 ↗
30. Sampaio-Pinto V. · 2020 · 18710.1007/978-3-030-43939-2_10 ↗
31. 10.1038/nrcardio.2014.3710.1038/nrcardio.2014.37 ↗
32. 10.1016/j.ebiom.2018.11.02610.1016/j.ebiom.2018.11.026 ↗
33. 10.1021/acsnano.9b0439710.1021/acsnano.9b04397 ↗
34. 10.3390/ijms2112440710.3390/ijms21124407 ↗
35. 10.1038/mt.2011.16410.1038/mt.2011.164 ↗
36. 10.1038/s41580-019-0158-710.1038/s41580-019-0158-7 ↗
37. 10.1021/acs.chemmater.9b0005010.1021/acs.chemmater.9b00050 ↗
38. 10.1021/acs.analchem.9b0462210.1021/acs.analchem.9b04622 ↗
39. 10.1021/acssensors.9b0076010.1021/acssensors.9b00760 ↗
40. 10.1007/s11060-013-1084-810.1007/s11060-013-1084-8 ↗
41. 10.1021/acsnano.6b0563010.1021/acsnano.6b05630 ↗
42. 10.3390/s1810317510.3390/s18103175 ↗
43. 10.1021/acsnano.0c0092110.1021/acsnano.0c00921 ↗
44. 10.1038/s41578-020-00277-610.1038/s41578-020-00277-6 ↗
45. 10.1093/cvr/cvaa02810.1093/cvr/cvaa028 ↗
46. 10.1016/j.ymthe.2021.01.02010.1016/j.ymthe.2021.01.020 ↗
47. 10.1039/C9NR09713A10.1039/C9NR09713A ↗
48. 10.1073/pnas.200356911710.1073/pnas.2003569117 ↗
49. 10.1080/08982104.2019.164928210.1080/08982104.2019.1649282 ↗
50. 10.1016/j.ultrasmedbio.2020.01.02710.1016/j.ultrasmedbio.2020.01.027 ↗
51. 10.1016/j.heliyon.2020.e0374810.1016/j.heliyon.2020.e03748 ↗
52. 10.1021/acsami.0c1204310.1021/acsami.0c12043 ↗
53. 10.1016/j.ijpharm.2020.11955910.1016/j.ijpharm.2020.119559 ↗
54. 10.1016/j.apmt.2020.10089710.1016/j.apmt.2020.100897 ↗
55. 10.1021/mp500835z10.1021/mp500835z ↗
56. 10.1097/RLI.000000000000073310.1097/RLI.0000000000000733 ↗
57. 10.1080/1061186X.2017.141936210.1080/1061186X.2017.1419362 ↗
58. 10.1016/j.jconrel.2016.10.00710.1016/j.jconrel.2016.10.007 ↗
59. 10.1121/1.364690510.1121/1.3646905 ↗
60. 10.1016/j.ces.2013.02.02110.1016/j.ces.2013.02.021 ↗
61. 10.1016/j.biomaterials.2019.11925010.1016/j.biomaterials.2019.119250 ↗
62. 10.1021/acs.langmuir.9b0089610.1021/acs.langmuir.9b00896 ↗
63. 10.1016/j.ultrasmedbio.2018.09.02210.1016/j.ultrasmedbio.2018.09.022 ↗
64. 10.2147/DDDT.S3156410.2147/DDDT.S31564 ↗
65. 10.1109/TUFFC.2016.261399110.1109/TUFFC.2016.2613991 ↗
66. 10.1016/j.addr.2008.03.00410.1016/j.addr.2008.03.004 ↗
67. 10.37191/mapsci-2582-4937-2(1)-01310.37191/mapsci-2582-4937-2(1)-013 ↗
68. 10.1016/j.arr.2019.10097910.1016/j.arr.2019.100979 ↗
69. 10.3390/cells906151810.3390/cells9061518 ↗
70. 10.3390/cells904093710.3390/cells9040937 ↗
71. 10.35713/aic.v1.i2.3910.35713/aic.v1.i2.39 ↗
72. 10.1177/153303382096419410.1177/1533033820964194 ↗
73. 10.3390/ijms2111408510.3390/ijms21114085 ↗
74. 10.1007/s12010-017-2478-410.1007/s12010-017-2478-4 ↗
75. 10.1016/j.jconrel.2018.12.02210.1016/j.jconrel.2018.12.022 ↗
76. 10.23937/2469-570X/141006610.23937/2469-570X/1410066 ↗
77. 10.1002/sctm.19-039110.1002/sctm.19-0391 ↗